Korean Drug Makers Caught Between GMPs And FTA To Compete Globally
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The Free Trade Agreement between South Korea and the U.S. - although not ratified yet by the two countries' legislative bodies - is already taking its toll on local South Korean pharmas seeking regulatory approval to produce generics, one of their main growth engines
You may also be interested in...
Korea FDA Moving To Strengthen Pharmacovigilance - APEC Harmonization Center Asia Regulatory Conference
SEOUL - Korea FDA said it is planning to introduce a set of pharmacovigilance-related policies including the establishment of a national drug safety management center to collect, assess, evaluate and disseminate drug safety information
Korea FDA Moving To Strengthen Pharmacovigilance - APEC Harmonization Center Asia Regulatory Conference
SEOUL - Korea FDA said it is planning to introduce a set of pharmacovigilance-related policies including the establishment of a national drug safety management center to collect, assess, evaluate and disseminate drug safety information
Korea-EU Free Trade Agreement Creates Another Threat To Local Korean Pharmas; Good For MNCs
SEOUL - The conclusion of the Free Trade Agreement talks on July 13 with the European Union could deal another blow to generic-dependent local South Korean pharma companies, already hit by a similar pact pending with the U.S